AbbVie (NYSE:ABBV) announced Wednesday that its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (NASDAQ:AMGN) blockbuster therapy, Otezla, in a Phase 4 head-to-head study for adults ...

After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. This time, the AbbVie and Boehringer Ingelheim-partnered biologic ...

AbbVie’s Skyrizi has already made a name alongside the likes of Novartis’ Cosentyx and Eli Lilly’s Taltz as a powerful biologic for psoriasis. Now, the AbbVie therapy showed it could help patients ...

Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI 100, reflecting 100% improvement on the Psoriasis Area and Severity Index, ...

AbbVie Inc ABBV announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab) ...

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...

Plaque psoriasis is a skin disease, so you’d think drugs that combat it would come in cream formulations. But such heavily advertised brands as Amgen’s Otezla and Abbvie’s Skyrizi and Humira are ...